Stifel Maintains Buy on Revolution Medicines, Raises Price Target to $230

Benzinga · 1d ago
Stifel analyst Laura Prendergast maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $215 to $230.